Engineering chemokines to develop optimized HIV inhibitors.
Curr Protein Pept Sci
; 6(3): 207-19, 2005 Jun.
Article
em En
| MEDLINE
| ID: mdl-15974948
ABSTRACT
Since the discovery that to enter target cells HIV uses receptors for the class of proteins known as chemokines, attempts have been made to generate anti-HIV molecules based on the chemokine ligands. A significant level of knowledge of the structure-activity relationships of chemokines has been amassed since the beginning of the 1990s. This, together with work that has elucidated the mechanisms underlying the inhibitory activity of chemokines, has guided not only the rational design of anti-HIV chemokine analogues, but also strategies by which chemokine variants with potent anti-HIV activity can be isolated from large libraries by phage display. This review summarizes the current knowledge about the structure-activity relationships and receptor biology of chemokines that is relevant to the development of analogues with anti-HIV activity. We present specific examples of engineered chemokine analogues with potent anti-HIV activity and describe the challenges that will need to be faced if these molecules are to be further developed for clinical applications. Finally, we discuss how these challenges might be met through further engineering of the molecules.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Engenharia de Proteínas
/
Quimiocina CCL5
/
Quimiocinas
/
Fármacos Anti-HIV
Limite:
Humans
Idioma:
En
Revista:
Curr Protein Pept Sci
Assunto da revista:
BIOQUIMICA
Ano de publicação:
2005
Tipo de documento:
Article
País de afiliação:
Suíça